Chris Miller, Ph.D.

Field Application Scientist - Elephas - Ph.D. in Molecular Biology - Stem cells & organoids - Genome Editing - Immunotherapies - Ironman Triathlete

New York, New York, United States

About

From Dallas, Texas - molecular biologist, human stem cell expert, botanist, Ironman triathlete, entrepreneur, nature lover, all things sports, Genome editor, storyteller. My expertise comes from a background in molecular biology working with iPSCs and adipose-derived MSCs for understanding the complexities of inherited retinal diseases and regenerative medicine, respectively. In cell culture experiments, I have experience in the production of retinal organoids, retinal pigmented epithelium, and incorporated prime editing/CrisprCas9 genomic editing strategies for understanding causality of inherited retinal diseases. Additionally, I have performed differentiation studies with adipose-derived MSCs using bioactive nanoparticles. Experience with western blots, RT-qPCR, immunofluorescent imaging, histological staining, bacterial studies, plasmid construction, golden gate assembly, Sanger and NGS sequencing, RNA sequencing, DNA and RNA isolation, and statistical analysis. I'm proud and honored to be part of the science community and to contribute to ongoing research in this field!

Experience

  • Sr. Field Application Scientist at Elephas
    Feb 2025 - Present · 1 yr 5 mos

  • Principal Scientist & Founder at Deep Space Therapeutics LLC
    Jan 2024 - Present · 2 yrs 6 mos

    Stealth company for Neuro-drug development in Parkinson’s, Alzheimer’s, PTSD, depression, amongst other applications in wound healing, and genomic editing.

  • Field Application Scientist at Unchained Labs
    Nov 2022 - Dec 2023 · 1 yr 2 mos

  • Postdoctoral Fellow at Massachusetts Eye and Ear
    Sep 2021 - Dec 2022 · 1 yr 4 mos

  • Postdoctoral Fellow at Harvard Medical School
    Sep 2021 - Dec 2022 · 1 yr 4 mos

    My research with the Ocular Genomics Institute involved the development of targeted therapies for inherited retinal diseases (IRDs). Specifically, I used ‘Prime Editing’ through golden gate assembly to introduce point mutations in PRPF3 & PRPF8(structural proteins for the splicesome complex). We used gene editing tools to better understand disease development over time for Retinitis Pigmentosa. If we discover the mechanisms for such gene mutations in patients who suffer from IRDs, enhanced targeted therapies can be developed to restore vision.